Asthma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Asthma is a chronic inflammatory
condition of the airways in which hypertrophy of bronchial smooth muscle and
mucous glands with plugging of small airways with thick mucus can occur. This
airway inflammation contributes to airway hyper-responsiveness, airflow
limitation, and respiratory symptoms and is at the root of the disease's
chronic nature. Based on the clinical features classified as mild intermittent,
mild persistent, moderate persistent, or severe persistent, depending on
symptom frequency and severity and lung function as assessed by forced
expiratory volume in 1 second (FEV1). Depending on symptoms, signs, and functional
assessment, asthma exacerbations are classified as mild, moderate, severe, and
impending respiratory failure.
- The incidence of Asthma in the USA varies from 158 to 187
cases per 100,000 populations, and the prevalence varies between 6.7 to
8.5 across all ages.
Thelansis’s “Asthma Market Outlook,
Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Asthma
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
KOLs insights
of Asthma across 8 MM market from the centre of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Asthma Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment